Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

August 11, 2017: By Jon Swedien

Ocular Therapeutix logoOcular Therapeutix’ cash, cash equivalents, and marketable securities totaled $66 million at the end of Q2-2017, the Bedford, Massachusetts, company announced Aug. 8.

Cash used in operating activities was $11.3 million in Q2-2017, compared with $9.8 million in Q2-2016, Ocular Therapeutix said. Total costs and operating expenses for Q2-2017 were $18.8 million, compared with $11.5 million in Q2-2016, the company said.

Ocular Therapeutix reported a net loss of approximately $18.7 million in Q2-2017, compared with a net loss of $11.4 million in Q2-2016. The Q2-2017 results include $2.1 million in non-cash charges for stock-based compensation and depreciation, compared with $1.7 million in such non-cash charges in Q2-2016.

The company is working to obtain approval for its lead product candidate, Dextenza, a proposed treatment for pain after ophthalmic surgery.

In mid-July, Ocular Therapeutix received a complete response letter (CRL) from the US FDA for its resubmitted new drug application (NDA) for Dextenza due to deficiencies in manufacturing and testing.

It was Dextenza’s second CRL related to plant issues.

Ocular Therapeutix made $400 thousand in revenues during Q2-2017 from product sales of ReSure Sealant, a product indicated for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022